Benzinga··Globe NewswireLiminatus Pharma Prices $4M Share Offering to Fund Immuno-Oncology Pipeline
Liminatus Pharma prices $4M share offering to fund immuno-oncology pipeline development, specifically advancing CD47-blockade therapeutic programs.
LIMNLIMNWwarrantspublic offering